Streicher et al. observed that despite drug therapy, LDL-apheresis significantly stimulates the residual LDL-receptor expression in FH via the reduction of available extracellular cholesterol resulting in delayed reappearance of hypercholesterolemia in between treatments [181]. This evidence concerns the gene LDLR and Hypercholesterolemia.